Azerbaijan Keputusan Tingkat Bunga
Di Azerbaijan, Keputusan Suku Bunga mewakili suku bunga kebijakan resmi yang ditetapkan oleh Bank Sentral Azerbaijan. Suku bunga ini mempengaruhi kebijakan moneter dan dapat mempengaruhi aktivitas ekonomi dan inflasi.
A higher than expected figure should be seen as positive (bullish) for the AZN while a lower than expected figure should be seen as negative (bearish) for the AZN.
Chart
History
| Tanggal | Time | Previous | Consensus | Aktual | ||
|---|---|---|---|---|---|---|
| Next Release Sep 23, 2026 | 06:00 | — | — | |||
| Jul 31, 2026 | 06:00 | 6.5% | 6.5% | |||
| Jun 24, 2026 | 07:00 | 6.5% | 6.5% | 6.5% | ||
| May 06, 2026 | 06:00 | 6.5% | 6.5% | 6.5% | ||
| Apr 02, 2026 | 07:00 | 6.5% | 6.5% | 6.5% | ||
| Feb 04, 2026 | 06:00 | 6.75% | 6.75% | 6.5% | ||
| Dec 10, 2025 | 07:00 | 7% | 7% | 6.75% | ||
| Oct 22, 2025 | 06:00 | 7% | 7% | 7% | ||
| Sep 10, 2025 | 07:00 | 7% | 7% | 7% | ||
| Jul 23, 2025 | 06:00 | 7.25% | 7.25% | 7% | ||
| Jun 11, 2025 | 07:00 | 7.25% | 7.25% | 7.25% |
Berita (AZN)
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for core earnings and revenue growth.
RTTNews | 45 days ago
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris
The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat certain rare diseases. Soliris is a medicine used to treat adults and children with paroxysmal nocturnal haemoglobinuria or PNH...
RTTNews | 833 days ago
Amazon, Microsoft, Pfizer To Invest Billions In French Projects
Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | 850 days ago
